Weekly systemic cisplatin plus locoregional hyperthermia: An effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area
Weekly systemic cisplatin plus locoregional hyperthermia: An effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area
复制标题
DOI：
10.1080/02656730701549359
复制
发表时间：
2007-01-01
影响因子：
3.1
通讯作者：
Van der Zee, Jacoba
中科院分区：
文献类型：
--
作者：
Franckena, Martine;De Wit, Ronald;Van der Zee, Jacoba
目的：先前照射区域内复发宫颈癌的患者对化疗反应不佳。我们用同步顺铂和热疗（CDDP+HT）治疗这些患者，并研究了反应、毒性、姑息效应和生存率。材料和方法：1992年至2005年期间，47名患者接受了CDDP+HT。通过妇科检查和 CT 扫描评估疗效。通用毒性标准（CTC）用于评估毒性和姑息效应。采用Kaplan-Meier法估计生存率，Cox回归分析评估预后因素的影响。结果：客观缓解率为55%，74%患者获得姑息治疗，19%患者可手术。目前，两名患者在治疗后 9 年零 18 个月以上时没有患病，另外 2 名患者一直没有患病，直到因其他原因死亡。中位生存期为 8 个月，并受无病间隔持续时间和肿瘤直径的影响。 36%的患者出现3-4级血液学毒性，肾毒性最高为2级。结论：CDDP+HT对复发性宫颈癌患者有较高的缓解率和可接受的毒性。
Purpose: Patients with recurrent cervical carcinoma within a previously irradiated area respond poorly to chemotherapy. We have treated these patients with simultaneous cisplatin and hyperthermia ( CDDP+HT) and investigated response, toxicity, palliative effect and survival.Materials and methods: Between 1992 and 2005 47 patients received CDDP+HT. Response was evaluated by gynaecologic examination and CT-scan. The Common Toxicity Criteria ( CTC) were used for evaluation of toxicity and palliative effect. The Kaplan-Meier method was used to estimate survival, and Cox regression analysis to evaluate the influence of prognostic factors.Results: The objective response rate was 55%, palliation was achieved in 74% and operability in 19% of patients. Two patients are currently disease free at 9 years and 18+months following treatment and 2 remained disease free until death by other causes. The median survival was 8 months and was influenced by duration of disease free interval and tumour diameter. Grade 3-4 haematological toxicity was observed in 36% of patients and renal toxicity was maximum grade 2.Conclusion: CDDP+HT results in a high response rate and acceptable toxicity in patients with recurrent cervical cancer.